Metropolis Healthcare Limited (METROPOLIS) Financial Results — Revenue ₹1.38 L Cr

1 Financial Results 🔴 High Importance Neutral 📄 PDF

Revenue: ₹1.38 L CrNet Profit: ₹4,323.62 Cr

📢 Key Event
Board approved FY2026 audited results, interim dividend, and auditor change to Deloitte Haskins & Sells.

🔄 What Changed
Net profit increased to ₹4323.62 crores; auditor changed from B S R & Co. LLP to Deloitte Haskins & Sells; Dr. Nilesh Shah moved to advisory role; 3:1 bonus issue announced.

🔮 What's Next
The company did not provide explicit future financial guidance or deadlines in the document.

💡 Investor Takeaway
Shareholders receive a ₹1 interim dividend and benefit from a new auditor appointment, while management changes signal leadership transition.

Metropolis Healthcare reported a net profit of ₹4323.62 crores for FY2025-26, up from ₹21170.01 lakhs last year, with earnings per share at [amount context mismatch] and an interim dividend of ₹1 per share approved on May 19, 2026, payable by June 19. The company appointed Deloitte Haskins & Sells as its new statutory auditor, replacing B S R & Co. LLP, effective May 13, 2026, while Dr. Nilesh Shah transitioned to an advisory role. The auditor confirmed an unmodified opinion on consolidated financials, which included unadjusted subsidiary figures totaling ₹5,763.67 lakhs in assets and ₹889.54 lakhs in net profit before consolidation adjustments. Business acquisitions in pathology and diagnostics added ₹11,611 lakhs to purchase consideration, and a 3:1 bonus issue was announced. The filing also noted regulatory impacts from new labour codes and a reduced tax demand of ₹3,880 lakhs.

2 Financial Results 🔴 High Importance Neutral 📄 PDF

Revenue: ₹425 CrNet Profit: ₹51

📢 Key Event
Metropolis Healthcare reported Q4FY26 results showing 23% YoY revenue growth to INR 425 crores and 75% YoY PAT growth to INR 51 crores.

🔄 What Changed
75% YoY PAT growth to INR 51 crores and 23% YoY revenue growth to INR 425 crores

🔮 What's Next
The Board approved a dividend of ₹1 per share.

💡 Investor Takeaway
Shareholders see improved profitability and dividend approval as positive signals of financial strength.

Metropolis Healthcare reported a 23% YoY revenue increase to INR 425 crores in Q4FY26, driven by 11% patient volume growth and 20% B2C revenue growth, while PAT rose 75% YoY to INR 51 crores, supported by strong operational efficiency and network expansion beyond 5,000 centres.

3 Financial Results 🔴 High Importance Neutral 📄 PDF

Revenue: ₹1.38 L CrNet Profit: ₹4,323.62 Cr

📢 Key Event
Metropolis Healthcare announced management changes including Dr. Nilesh Shah's transition to advisory role and Deloitte Haskins & Sells' appointment as new statutory auditor.

🔄 What Changed
Revenue grew 69.9% YoY to ₹1,67,143.03 lakhs; net profit reached ₹19,118.20 lakhs; total assets increased to ₹2,15,896.53 lakhs; Deloitte appointed as auditor; Dr. Nilesh Shah moved to advisory role effective 14 May 2026.

🔮 What's Next
The filing does not include explicit future financial guidance or deadlines beyond the disclosed management transition and audit arrangements.

💡 Investor Takeaway
The company's strong revenue growth and clean audit signal robust financial health, but the management transition may introduce execution risks for future performance.

Metropolis Healthcare reported a 69.9% year-on-year revenue jump to ₹1,67,143.03 lakhs for FY2026, driven by strategic acquisitions, while net profit rose to ₹19,118.20 lakhs and total assets grew to ₹2,15,896.53 lakhs as of 31 March 2026, supported by a clean audit opinion and new auditor appointment.